ALCHEMIA SHARES PLUNGE

Written on the 28 October 2014

ALCHEMIA SHARES PLUNGE

SHARES in Alchemia (ASX:ACL) have dived 83 per cent after the company announced its metatastic colorectal cancer trial had failed.

The treatment tested Alchemia’s HyAct technology formulated with chemotherapeutic drug irinotecan over using irinotecan alone.

HA-irinotecan did not improve progression free survival in patients.

Alchemia CEO Thomas Liquard says the company will conduct an in-depth review of the trial.

“We are extremely disappointed in the outcome of this trial and extend our appreciation to trial investigators, the clinical sites and the hundreds of patients who participated in this study,” Liquard says.

“We expect to report back to the scientific community and the market with further details on our data reviews and corporate strategy early in 2015.”

The drug development company’s financial position includes $8.9 million in cash and a $6.5 million research and tax development tax incentive to be received next month.

ACL is trading at $0.098 per share.


Latest News

COMMBANK FACES 'VERY LARGE' CLASS ACTION LAW SUIT OVER MONEY LAUNDERING SCANDAL

THE Commonwealth Bank is facing a potential massive class action from shareholders because of a big drop in its sh...

NATIONAL STORAGE LIFTS PROFIT AND REVENUE ON ACQUISITION PROGRAM, HIGHER CHARGES

NATIONAL Storage REIT (ASX: NSR) has more than doubled its after tax profit to $103.4 along with a 47 per cent lif...

REJECT SHOP THE LATEST IN A STRING OF RETAILER CASUALTIES

THE PROFIT margin of discount retailer The Reject Shop (ASX: TRS) has been hammered down 27.8 per cent following a...

VOCUS CHAIRMAN STEPS DOWN AFTER $1.5 BILLION LOSS, NO DIVIDEND PAYOUT

CHAIRMAN of Australian internet network company Vocus (ASX: VOC), David Spence, will step down after the company p...

Related News

COMMBANK FACES 'VERY LARGE' CLASS ACTION LAW SUIT OVER MONEY LAUNDERING SCANDAL

THE Commonwealth Bank is facing a potential massive class action from shareholders because of a big drop in its sh...

REPORTING SEASON WRAP: WEDNESDAY HIGHLIGHTS

The A2 Milk Company (ASX:A2M) has almost tripled its profits and increased total revenue by 56 per cent off the ba...

THE MOTHER OF THREE WHO HAS SHARK TANK'S ANDREW BANKS AND STEVE BAXTER FIGHTING TO INVEST WITH HER

NOT every entrepreneur on Shark Tank Australia convinces the 'sharks' that their business is worthy of inv...

DARK DAYS AHEAD FOR AUSTRALIAN RETAIL AS REPORT FORECASTS MAJOR INDUSTRY ROUT

ALMOST 1,600 retail businesses are at risk of imminent collapse, including 21 major retailers with turnovers of more ...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter